|
CA2900508A1
|
|
Cabazitaxel composition
|
|
WO2013088216A1
|
|
Mixed poloxamer excipients
|
|
WO2011104625A1
|
|
Cyclopolysaccharide compositions
|
|
WO2011104631A1
|
|
Sn-38 compositions
|
|
US2012015995A1
|
|
Bendamustine anionic-catioinic cyclopolysaccharide compositions
|
|
WO2010097700A1
|
|
Bendamustine cyclopolysaccharide compositions
|
|
CN101389343A
|
|
Doxorubicin formulations for anti-cancer use
|
|
US2007135473A1
|
|
Method of treating tumors with azaxanthones
|
|
WO2005090570A1
|
|
Therapeutic compositions and methods for treating diseases that involve angiogenesis
|
|
CA2569585A1
|
|
Compositions for oral administration of campothecin and its analogs
|
|
WO03059382A2
|
|
Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression
|
|
US7204997B2
|
|
Responsive microgel and methods related thereto
|
|
CA2408652A1
|
|
A method for designing and screening random libraries of compounds
|
|
US6387633B1
|
|
Method for identifying unstable genes
|
|
US6656459B2
|
|
Compositions of non-ionic block copolymers to treat autoimmune and inflammatory diseases, and to reduce graft/implantation, and methods of use thereof
|
|
CA2408387A1
|
|
A ligand for enhancing oral and cns delivery of biological agents
|
|
US6696274B2
|
|
Ligand for enhancing oral and CNS delivery of biological agents
|
|
US7256180B2
|
|
Compositions and methods for inducing activation of dendritic cells
|
|
CA2407700A1
|
|
Compositions and methods for inducing activation of dendritic cells
|
|
WO0157067A1
|
|
Ligand for vascular endothelial growth factor receptor
|
